Nav: Home

Study may help reassure women taking tamoxifen for breast cancer

October 04, 2016

MAYWOOD, IL. -- A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.

The multi-center study was published in the Nature journal npj Breast Cancer. Corresponding author is Kathy S. Albain, MD, FACP, FASCO and first author is Ronald K. Potkul, MD, FACS, FACOG. Dr. Albain is a professor in the department of medicine, division of hematology/oncology, and Dr. Potkul is chair of the department of obstetrics and oncology of Loyola University Chicago Stritch School of Medicine.

The study enrolled 296 eligible postmenopausal breast patients with a type of early-stage breast cancer called estrogen receptor-positive. Patients were randomly assigned to take tamoxifen alone or tamoxifen plus the hormone progestin. They were followed and assessed at years two and five. Researchers predicted that taking progestin would decrease the risk of abnormalities that can develop into uterine cancer. Such abnormalities occur in the endometrium (inner lining of the uterus).

At year two, the primary time point, researchers evaluated 89 women who took tamoxifen alone and 80 women who took tamoxifen plus progestin. There were five endometrial abnormalities in the tamoxifen-alone group and one abnormality in the tamoxifen-plus-progestin group. This difference was not statistically significant. All abnormalities were benign. Only one additional benign abnormality was found at five years. No cancers were detected at two years or five years.

Two years after treatment began, only 6 percent of the patients in the tamoxifen-alone group, and 3.6 percent in both groups combined had benign endometrial abnormalities. Based on previous studies, researchers had projected that 30 percent of the women in the tamoxifen-alone group would show endometrial abnormalities.

Dr. Albain said the reason the abnormality rate was much lower than expected most likely was due to the study's screening requirements. All women recruited for the study underwent uterine ultrasound exams before taking tamoxifen. If the ultrasounds showed a thickening of the inner lining of the uterus greater than 5 mm, a biopsy was performed. If the biopsy showed an endometrial abnormality, the woman was excluded from the study.

"For women who are concerned about taking tamoxifen to treat or prevent breast cancer, our study suggests that a normal ultrasound before treatment may provide additional reassurance," Dr. Albain said.

Tamoxifen is a highly effective drug that is used both to treat breast cancer and help prevent breast cancer in healthy women who are at high risk of developing the disease.

"However, many women who would benefit from taking tamoxifen fail to do so because they fear getting endometrial cancer," Dr. Potkul said. "Our study found that for women who did not have endometrial abnormalities when they began taking tamoxifen, there was a very low rate of developing pre-malignant conditions."

The median age of the women in the study was 59.5 years. They underwent endometrial ultrasounds at the beginning of the study and after two years and five years. After two years, 67 percent of the women in the tamoxifen-alone group had a thickening of the inner lining of the uterus greater than 5 mm, compared with 60 percent of the women in the tamoxifen-plus-progestin group. This difference was not statistically significant. All women who had a thickness greater than 5 mm underwent subsequent biopsies. The biopsies revealed five cases of endometrial abnormalities in the tamoxifen group: four cases of proliferative endometrium (more cells than normal lining the uterus) and one case of simple hyperplasia (non-malignant clumping of cells). One woman in the tamoxifen-plus progestin group had an abnormality (proliferative endometrium). None of the abnormalities in either group developed into uterine cancer.

Although there were more endometrial abnormalities in the tamoxifen-alone group, the difference was not large enough to be statistically significant. It would require a follow-up trial with thousands of women to determine whether adding progestin to tamoxifen truly reduces the risk of uterine cancer.

Researchers concluded: "These data could potentially reassure certain postmenopausal women who fear endometrial side effects of tamoxifen, but would otherwise benefit from instituting this important adjuvant breast cancer and breast cancer chemoprevention therapy. However, validation in a larger trial is needed first before changing practice in all asymptomatic postmenopausal women."
-end-
The study was funded by the National Cancer Institute (NCI) and administered by SWOG, a global network of researchers who design and conduct cancer clinical trials. SWOG (formerly the Southwest Oncology Group) is one of the five cooperative groups in the NCI's National Clinical Trials Network. In addition to Drs. Albain and Potkul, other co-authors are Joseph Unger, Robert Livingston, Katherine Crew, Sharon Wilczynski, Caryl Salomon, Barbara Smith, Lucas Wong, David Campbell, David Einspahr, Garnet Anderson, Dawn Hershman, Gary Goodman, Powel Brown and Frank Meyskens.

Loyola University Health System

Related Postmenopausal Women Articles:

The role of weight in postmenopausal women's longevity
In a large multiethnic study, being underweight was linked with an increased risk of early death among postmenopausal women.
Surprising health changes among postmenopausal women who marry or divorce
Contrary to previous data, a new study finds that some health measures in postmenopausal women, such as body mass index (BMI), tend to worsen if the women marry and to improve if they divorce or separate from their partner.
New study shows anxiety impairing quality of life for postmenopausal women
Whether anxiety increases common menopause symptoms such as hot flashes and sleep disruption or whether these symptoms cause increased anxiety remains an ongoing debate.
Abaloparatide benefits a wide range of postmenopausal women with osteoporosis
A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.
Estrogen patch in newly postmenopausal women may reduce Alzheimer's risk
Can estrogen preserve brain function and decrease the risk of Alzheimer's disease when given early in menopause?
Saturated fatty acids linked to breast cancer in postmenopausal women
Fatty acids in the breast may be useful indicators of cancer in postmenopausal women, according to a new study published online in the journal Radiology.
Abaloparatide may help prevent fractures in postmenopausal women with osteoporosis
The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests.
Periodontal disease associated with increased breast cancer risk in postmenopausal women
Postmenopausal women with periodontal disease were more likely to develop breast cancer than women who did not have the chronic inflammatory disease.
Continuous joint use of estrogen and progestin lowers risk of EC in postmenopausal women
Adding continuous progestin to estrogen has been shown to lower the risk of endometrial cancer in postmenopausal women according to a study published Dec.
Physical activity has greater impact on body composition in postmenopausal women
Everyone knows that exercise is good for you, regardless of your age.

Related Postmenopausal Women Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...